ArticleWorld journal of microbiology & biotechnology2026
Deciphering the potentiality of Andrographolide derivatives against Pseudomonas aeruginosa: in vitro analysis and mechanistic insights.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- N-sulfonylated indole hydrazone hybrid targeting Staphylococcus aureus with compelling antibiofilm and membrane-disrupting properties.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Discovery of new bioactive secondary metabolites from the stem bark of oroxylum indicum: isolation, structural identification, antimicrobial and cytotoxicity assessment.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Antimicrobial assessment and scanning electron microscopy analysis of sesquiterpene lactones isolated from the leaves of Inula racemosa Hook. f.Archives of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antimicrobial resistance (AMR) has become a global challenge in the treatment of infectious diseases. In 2024, the WHO updated the bacterial priority pathogens list, underscoring several high-priority resistant bacteria of major public health concern. Among these, Gram-negative bacteria are particularly prone to antibiotic resistance due to their complex outer membrane architecture. The reduced effectiveness of current therapies has resulted in an increasing global disease burden and mortality rates. Pseudomonas aeruginosa colonizes the upper respiratory tract and is frequently associated with secondary infections during viral pneumonia, contributing to increased complications. In the present study, we investigated the potentiality of plant-based Andrographolide and its derivatives. Initial screening identified four compounds along with the parent molecule (Andrographolide) that exhibited promising antipseudomonal activity, and among them, IIIM(ND)-RS03 demonstrated greater inhibitory activity, which was further supported by Minimum Bactericidal Concentration (MBC) profiling, which shows a markedly lower bacterial colony count compared with the remaining molecules. Time-kill kinetics analysis revealed the bactericidal nature of the potent molecule, along with noteworthy biofilm inhibition and disruption potential with respect to the untreated control. Mechanistic studies revealed pronounced morphological alterations in bacterial cells, as confirmed by scanning electron microscopy analysis. Moreover, it can trigger multiple pathways that lead to cell death, including membrane disruption, increased permeability, reduction in intracellular ATP levels, and enhanced ROS generation. Taken together, the antibacterial activity as well as mechanistic insights, the present study underlines the potential of the selected molecule as a promising lead for the development of next-generation antimicrobial agents.
Indexed as
Identifiers
41849041What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.